frontsFront
Anti-amyloid treatment
Antibodies that lower amyloid plaques in early symptomatic Alzheimer’s disease, with ARIA monitoring.
Overview
Lecanemab and donanemab are the current US-approved examples. They need amyloid confirmation, infusion capacity, and MRI. They are not indicated for vascular, Lewy body, or frontotemporal dementia as disease-modifying care.
Anti-amyloid treatment: how this front works · animated schematic, not to scale